Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Dec 20, 2022 3:00pm
102 Views
Post# 35182908

RE:Newbies...ignore the vapid FUD attempts...

RE:Newbies...ignore the vapid FUD attempts...No, not necessarily the case at all... I'm a long term investor, and it was through my own stupidity that I believed the crock of sh%$^e that pumpers were spewing about this company over 10 years ago... Trials came and went, more delay. ONe year we would be told OS was more important, that next it was PFS. The old CEO hired his own family members into the company with zero experience.

At one point I was down 95% on this stock, and had tied up everything in it. Wow.. how dumb was I...

CEO changed and Matt said we were now a Breast Cancer company... nope... we got great phase II results, all primed and ready for a Phase III (fast track status from FDA)... then the company goes off down yet another cul-de-sac... another 5 years has gone by, and we still have neither a partner, NOR conclusive results that Pela + Pax + CPI is any better than Pela + PAX (IND-213). This company has an incomprehensible trail of delays, hints of efficacy but never anything statistical... They've had 3 CMOs since the Phase II results, and the latest one needs a teleprompter... it's pathetic.

Now while the preliminary panc data looks awesome, it is small numbers yet again, and there is no frigging way they can havbe approval for product launch before end 2027. It's been a total sh tshow... and that is why I post... caveat emptor.

I'm a very p*ssed off long term shareholder. And seeing the endless pumps, and fairy valuations for a buyout makes my blood boil... those charlatans are the paid ones, paid shills.

I want this company to succeed, if nothing more than to get the F%$^ out of it, with the shirt on my back still.. I do not work for any funds. Just beware those who tell you this is a done deal... 26 years says otherwise... be careful, and buy only on dips, and sell into pending news, as it 100% drops afterwards, due to disappointment.

glta

<< Previous
Bullboard Posts
Next >>